-
Chiasma Files Mycapssa European Application For Acromegaly
Tuesday, June 29, 2021 - 7:03am | 177Read More...Chiasma Inc (NASDAQ: CHMA) submitted a marketing application to the European Medicines Agency seeking approval of Mycapssa (oral octreotide capsules) as maintenance therapy for adults with acromegaly. The application is supported by positive results from Phase 3 MPOWERED non-...
-
Chiasma's Mycapssa Associated With Positive Patient-Reported Outcomes In Acromegaly Patients
Friday, May 28, 2021 - 8:02am | 270Read More...Chiasma Inc (NASDAQ: CHMA) has presented patient-reported outcomes (PROs) data from its MPOWERED Phase 3 trial of Mycapssa for acromegaly, a hormonal disorder in which the pituitary gland produces too much growth hormone. Data demonstrated that study patients reported significantly...
-
Chiasma's Mycapssa Improves Acromegaly Related Symptoms After Switching From iSRLs
Monday, March 22, 2021 - 8:42am | 275Read More...Chiasma Inc (NASDAQ: CHMA) has announced new data from the MPOWERED Phase 3 trial of Mycapssa as the first oral therapy to treat acromegaly. Chiasma presented the data at the Endocrine Society's annual meeting. The data from MPOWERED showed that Mycapssa improved clinical...
-
Chiasma Plunges 14%; Feuerstein Source Says FDA Will Reject Co.'s Therapy Capsules
Thursday, April 14, 2016 - 10:05am | 258Read More...Shares of Chiasma Inc (NASDAQ: CHMA) plunged more than 14 percent Thursday morning ahead of the U.S. Food and Drug Administration's decision on Friday to approve or reject the company's therapy. Chiasma is a biopharmaceutical company that focuses on the treatment of orphan diseases. The...
